Assesment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease.
Latest Information Update: 09 Nov 2021
Price :
$35 *
At a glance
- Drugs Mibampator (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 01 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Feb 2011 Planned end date changed from 1 Oct 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.